DBV Technologies
Corporate brand
UnclaimedFrench biopharmaceutical company developing epicutaneous immunotherapy for food and other allergies.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
DBV Technologies is a publicly listed French biopharmaceutical company headquartered in Bagneux, France. Founded in 2002, the company develops treatments intended to address food allergies, particularly peanut and cow's-milk allergy, as well as pediatric allergy conditions for which treatment options have historically been limited. Its research and product strategy is built around Viaskin, an epicutaneous immunotherapy platform that uses a wearable patch to deliver an allergen or antigen to intact skin. The approach is designed to expose the immune system to the relevant substance without injecting it and without requiring the allergen to enter the bloodstream in the same way as conventional systemic administration. The company was established by pediatric gastroenterologist Pierre-Henri Benhamou, engineer Bertrand Dupont, and neonatology professor Christophe Dupont. The founders supplied the initial startup capital, after which DBV Technologies raised approximately €40 million in venture financing between December 2003 and January 2011. In March 2012, it completed an initial public offering on the NYSE Euronext market that raised €40.5 million, according to the referenced company history. DBV Technologies subsequently operated as an international clinical-stage biopharmaceutical business with activity in France, the United States, and Europe. DBV's best-known development program is Viaskin Peanut, an investigational treatment intended to reduce the risk associated with accidental peanut exposure by increasing a patient's tolerance to peanut protein. The program received Fast Track designation from the U.S. Food and Drug Administration. In September 2014, the company reported positive results from the VIPES, or Viaskin Peanut Efficacy and Safety, clinical trial, describing evidence of peanut desensitization. The company has also developed Viaskin Milk for cow's-milk allergy and has described its E-patch process as a standardized patch-based method for allergy testing and allergen delivery. DBV Technologies is positioned as a specialist innovator in allergy immunotherapy rather than as a broad pharmaceutical conglomerate. Its differentiation rests on the convenience and administration profile of an adhesive patch, the focus on pediatric and food-allergy populations, and the goal of avoiding direct transfer of the administered allergen into the blood. The company's products remain tied to clinical development and regulatory evaluation, so its commercial position depends on trial outcomes, regulatory decisions, manufacturing quality, and the ability to demonstrate clinically meaningful protection for patients with serious allergies.
History
DBV Technologies was founded in France in 2002 by Pierre-Henri Benhamou, a physician specializing in pediatric gastroenterology; Bertrand Dupont, an engineer educated at Arts et Métiers ParisTech; and Christophe Dupont, a professor who headed the neonatology department at Saint Vincent Hospital in Paris. The founders provided the initial capital for the venture and established the company around the development of patch-based approaches to allergy diagnosis and immunotherapy. The company's central technological concept became Viaskin, an epicutaneous patch intended to place an allergen or antigen on intact skin. Unlike approaches that administer allergens by injection or require oral exposure, the Viaskin concept is designed to deliver the active substance through the skin while avoiding transfer into the bloodstream. DBV Technologies presented this method as a way to pursue allergen desensitization with a potentially convenient format, particularly for children and patients with food allergies. During its early financing period, the company obtained approximately €40 million in venture funding between December 2003 and January 2011. This financing supported the development of its platform and candidate products. DBV Technologies later went public in March 2012 through an initial public offering on the NYSE Euronext exchange, raising €40.5 million according to the referenced historical account. The listing gave the company access to public-market capital as it advanced its clinical programs. DBV's product work focused principally on food allergy, including peanut allergy and cow's-milk allergy, and on pediatric allergy populations. Its two principal products described in the reference material were Viaskin Peanut and Viaskin Milk. Viaskin Peanut was developed to help patients tolerate controlled exposure to peanut protein, with the intended benefit of lowering the risk of a severe systemic reaction following accidental exposure. Viaskin Milk was directed toward cow's-milk allergy. The company also developed the E-patch process, described as a standardized, ready-to-use patch format for allergy testing that preserves the relevant allergenic agents. Clinical development became the principal turning point in the company's public profile. The Viaskin Peanut program received Fast Track designation from the U.S. Food and Drug Administration, reflecting the regulatory importance of the condition and the program's potential to address an area of unmet medical need. In September 2014, DBV Technologies announced successful results from the VIPES clinical trial, whose full name was Viaskin Peanut Efficacy and Safety. The company characterized the results as demonstrating peanut-allergy desensitization. The company has been led, according to the referenced account, by Chief Executive Officer Daniel Tassé, with Pascal Wotling holding responsibility for technical operations and quality. DBV Technologies' continuing identity is that of a focused biopharmaceutical developer rather than a diversified drug manufacturer. Its business scope remains centered on allergy immunotherapy, patch-based delivery, clinical evidence, and regulatory advancement in France, the United States, and Europe. Because the referenced material does not establish a fully commercialized product portfolio or later regulatory outcomes, the status and market availability of individual Viaskin candidates should be verified against current company and regulatory disclosures.
- 2014
VIPES clinical-trial results announced
[1]The company reports successful results from its Viaskin Peanut Efficacy and Safety trial in peanut-allergy desensitization.
- 2012
Initial public offering
[1]DBV Technologies raises €40.5 million in a March initial public offering on the NYSE Euronext exchange.
- 2011
Early venture-financing period concludes
[1]The referenced company history records approximately €40 million in venture financing raised between December 2003 and January 2011.
- 2003
Venture-financing period begins
[1]The company begins a period in which it raises approximately €40 million in venture funding through January 2011.
- 2002
DBV Technologies is founded
[1]Pierre-Henri Benhamou, Bertrand Dupont, and Christophe Dupont establish the French biopharmaceutical company.
Products and positioning
A specialist biopharmaceutical innovator focused on non-invasive, patch-based immunotherapy for food and pediatric allergies.
Epicutaneous peanut immunotherapy
Viaskin Peanut
Viaskin Peanut is DBV Technologies' principal peanut-allergy development program. It uses the Viaskin patch concept to place peanut allergen on intact skin with the aim of increasing a patient's tolerance to peanut exposure. The intended clinical benefit is to reduce the likelihood or severity of a systemic allergic reaction after accidental exposure. The program received FDA Fast Track designation, and the company reported positive desensitization results from the VIPES clinical trial in 2014.
Epicutaneous cow's-milk immunotherapy
Viaskin Milk
Viaskin Milk is a development program directed at cow's-milk allergy. It applies the company's patch-based epicutaneous delivery approach to a pediatric food-allergy indication. The referenced material identifies it as one of DBV Technologies' two principal products, but does not provide sufficient information to establish its current clinical phase, regulatory status, or commercial availability.
Allergen and antigen delivery platform
Viaskin technology
Viaskin is DBV Technologies' patch-based technology for administering allergens or antigens to intact skin. The platform is designed to avoid direct transfer of the administered substance into the blood and to support non-invasive immunotherapy. Its principal application in the available material is the development of treatments for food allergy, especially peanut and cow's-milk allergy.
Allergy testing and patch process
E-patch
The E-patch is a patented process described by DBV Technologies for standardized, ready-to-use patch testing and allergen delivery. The process is intended to preserve allergenic agents in a usable state and support reliable allergy testing, including testing involving children. The available reference does not specify a separate commercial product range or current market status.
Controversies
2021
Court dismisses DBV Technologies class-action complaint without prejudice
The U.S. District Court for the District of New Jersey granted DBV Technologies' motion to dismiss the Second Amended Class Action Complaint without prejudice. The court said the complaint was deficient and allowed plaintiffs until September 30 to amend it.
Brand decisions
2014
Positive VIPES results for Viaskin PeanutOtherBackground
The company evaluated Viaskin Peanut in the Viaskin Peanut Efficacy and Safety clinical trial.
Action taken
DBV Technologies announced successful trial results relating to peanut-allergy desensitization.
Aftermath
The announcement advanced the public clinical narrative around Viaskin Peanut, while the referenced material does not establish final regulatory approval or commercial launch.
2012
DBV Technologies chooses a public-market financing routeOtherBackground
After raising venture capital during its early development period, DBV Technologies pursued a public offering to support its biopharmaceutical and clinical-development activities.
Action taken
The company completed an initial public offering on the NYSE Euronext exchange in March 2012.
Aftermath
The offering raised €40.5 million and marked the company's transition to a publicly financed development-stage biopharmaceutical business.
IPO proceeds. €40.5 million raised (March 2012)
- FDA Fast Track designation for Viaskin PeanutOther
Background
DBV Technologies was developing a patch-based treatment for peanut allergy, a condition associated with potentially serious reactions and limited treatment options.
Action taken
The U.S. Food and Drug Administration granted Fast Track designation to the Viaskin Peanut clinical development program.
Aftermath
The designation supported regulatory engagement for the program, although the available source does not provide a subsequent approval decision.
Recent events
Reported
DBV Technologies completes $50 million ADS sale[4]
DBV Technologies reported that during the third quarter of 2026 it completed a sale of ADSs generating $50 million in gross proceeds to RA Capital Management.
Reported
Court dismisses DBV Technologies class-action complaint without prejudice[3]
The U.S. District Court for the District of New Jersey granted DBV Technologies' motion to dismiss the Second Amended Class Action Complaint without prejudice. The court said the complaint was deficient and allowed plaintiffs until September 30 to amend it.
Reported
DBV Technologies reports full-year 2019 financial results[5]
DBV Technologies reported its audited full-year 2019 financial results, including a net loss of €153.6 million. The company also provided a business update.
Reported
DBV Technologies prices $125 million global offering[6]
DBV Technologies announced the pricing of a global offering of ordinary shares and American Depositary Shares expected to raise approximately $125 million before commissions and expenses. The offering included a U.S. and international ADS offering and a European private placement; closing was expected on October 11, 2019, subject to customary conditions.
Sources9 sources
- 1DBV Technologiesen.wikipedia.org
- 2DBV Technologies official websitedbv-technologies.com
- 3Court dismisses DBV Technologies class-action complaint without prejudicefinanznachrichten.de
- 4DBV Technologies完成5,000万美元ADS出售finanznachrichten.de
- 5DBV Technologies公布2019财年全年财务业绩finanznachrichten.de
- 6DBV Technologies为全球发行定价1.25亿美元finanznachrichten.de
- 7DBV Technologies S.A.: DBV Technologies Reports First Half 2020 Financial Resultsfinanznachrichten.de
- 8DBV Technologies S.A.: DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updatesfinanznachrichten.de
- 9DBV Technologies S.A.: DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developmentsfinanznachrichten.de
Cite this profile: Cite the canonical profile. /brand-wiki/dbv-technologies · Editorial policy · How profiles are compiled